DLL3 CAR-T Therapy Targeting Brain Tumors

The purpose of this study is to assess the feasibility, safety and efficacy of Delta-like ligand 3 (DLL3)-specific CAR-T cell therapy in patients with DLL3 positive brain tumors including glioblastomas and diffused intrinsic pontine or midline gliomas (DIPG or DMG). Another goal of the study is to learn more about the function of the anti-DLL3 CAR-T cells and their persistency in patients.

Trial Details

NCT ID
NCT07180927
Phase
PHASE1 / PHASE2
Sponsor
Shenzhen Geno-Immune Medical Institute
Status
RECRUITING
Cancer Type
Brain Cancer
Interventions
  • 4SCAR DLL3 T cells
Locations (sample)
  • Shenzhen, Guangdong, China|22.54554,114.0683

Key Eligibility Criteria

  • abilities to understand and the willingness to provide written informed consent;
  • patients are ≥ 2 and ≤ 70 years old;
  • recurrent or refractory brain tumor patients with measurable lesions. Patients have received standard care of medication, such as gross total resec…
  • Karnofsky performance score (KPS) ≥ 60;

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Brain Cancer Trials on Trialify →